Alembic Pharmaceuticals Limited receives EIR from USFDA for Oncology Formulation facility

Alembic Pharmaceuticals Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at our Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28th February, 2024 to 8th March, 2024.

With this, for all our USFDA facilities, EIRs are in place.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 1020.60 as compared to the previous close of Rs. 1026.20. The total number of shares traded during the day was 8387 in over 883 trades.

The stock hit an intraday high of Rs. 1033.65 and intraday low of 1010.45. The net turnover during the day was Rs. 8544962.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 EIR USFDA OncologyFormulationFacility Panelav